Amedeo Smart

Free Medical Literature Service



Ovarian Neoplasms

  Free Subscription


1 BMC Cancer
1 Cancer Lett
2 Gynecol Oncol
1 Int J Gynaecol Obstet
1 PLoS One

    BMC Cancer

  1. FANG DD, Tao R, Wang G, Li Y, et al
    Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
    BMC Cancer. 2022;22:752.
    >> Share

    Cancer Lett

  2. RUSSO A, Zizhao Y, Heyrman GM, Cain BP, et al
    Versican secreted by the ovary links ovulation and migration in fallopian tube derived serous cancer.
    Cancer Lett. 2022 Jun 10:215779. doi: 10.1016/j.canlet.2022.215779.
    >> Share

    Gynecol Oncol

  3. PIEDIMONTE S, Bernardini MQ, Ding A, Laframboise S, et al
    Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Gynecol Oncol. 2022 Jul 9. pii: S0090-8258(22)00430.
    >> Share

  4. CADOO K, Simpkins F, Mathews C, Liu YL, et al
    Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    Gynecol Oncol. 2022 Jul 5. pii: S0090-8258(22)00421.
    >> Share

    Int J Gynaecol Obstet

  5. MI D, Zhang Y, Chen S
    Serum HE4 is associated with clinical prognostic factors and survival outcome in female patients with primary peritoneal carcinoma.
    Int J Gynaecol Obstet. 2022;158:352-358.
    >> Share

    PLoS One

  6. HAZAMA Y, Tsujioka T, Kitanaka A, Tohyama K, et al
    Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
    PLoS One. 2022;17:e0271245.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016